Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

The New England Journal of Medicine
Susan SwindellsWilliam R Spreen

Abstract

Simplified regimens for the treatment of human immunodeficiency virus type 1 (HIV-1) infection may increase patient satisfaction and facilitate adherence. In this phase 3, open-label, multicenter, noninferiority trial involving patients who had had plasma HIV-1 RNA levels of less than 50 copies per milliliter for at least 6 months while taking standard oral antiretroviral therapy, we randomly assigned participants (1:1) to either continue their oral therapy or switch to monthly intramuscular injections of long-acting cabotegravir, an HIV-1 integrase strand-transfer inhibitor, and long-acting rilpivirine, a nonnucleoside reverse-transcriptase inhibitor. The primary end point was the percentage of participants with an HIV-1 RNA level of 50 copies per milliliter or higher at week 48, determined with the use of the Food and Drug Administration snapshot algorithm. Treatment was initiated in 308 participants per group. At week 48, HIV-1 RNA levels of 50 copies per milliliter or higher were found in 5 participants (1.6%) receiving long-acting therapy and in 3 (1.0%) receiving oral therapy (adjusted difference, 0.6 percentage points; 95% confidence interval [CI], -1.2 to 2.5), a result that met the criterion for noninferiority for the ...Continue Reading

References

Apr 7, 2011·AIDS and Behavior·Carmen OrtegoJavier Vejo
Oct 9, 2013·Current Opinion in HIV and AIDS·William R SpreenJohn C Pottage
Oct 22, 2013·JAMA : the Journal of the American Medical Association·UNKNOWN World Medical Association
Aug 19, 2018·Retrovirology·Maureen OliveiraUNKNOWN Montreal Primary HIV (PHI) Cohort Study Group
Nov 13, 2018·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Ethel D WeldAllison L Agwu
Mar 5, 2020·The New England Journal of Medicine·Chloe OrkinWilliam R Spreen

❮ Previous
Next ❯

Citations

Mar 5, 2020·The New England Journal of Medicine·Judith S Currier
Jun 17, 2020·Expert Review of Clinical Pharmacology·Andrea GiacomelliStefano Rusconi
Jun 26, 2020·MMW Fortschritte der Medizin·Elke Oberhofer
Aug 24, 2020·New Directions for Child and Adolescent Development·Geoffrey Peter Garnett
Aug 30, 2020·Drugs·Kimberly K ScarsiCourtney V Fletcher
Apr 29, 2020·Nature Materials·Tanmay A KulkarniHoward E Gendelman
Mar 5, 2020·The New England Journal of Medicine·Chloe OrkinWilliam R Spreen
Jul 25, 2020·Nature Materials·Vicente SorianoCarmen de Mendoza
Sep 13, 2020·Current HIV/AIDS Reports·Elisa H Ignatius, Susan Swindells
Aug 21, 2020·Proceedings of the National Academy of Sciences of the United States of America·Yoshiaki NishimuraMichael S Kay
Aug 5, 2020·The Journal of Antimicrobial Chemotherapy·Giovanni GuaraldiCristina Mussini
Oct 29, 2020·Expert Opinion on Pharmacotherapy·Diana Canetti, Vincenzo Spagnuolo
Sep 15, 2020·Journal of Acquired Immune Deficiency Syndromes : JAIDS·S SpringI Woolley
Dec 19, 2020·Current Opinion in Infectious Diseases·John Thornhill, Chloe Orkin
Nov 12, 2020·Current Opinion in Pharmacology·Yali SangFener Chen
Dec 4, 2020·The Lancet. HIV·Sharon R LewinUNKNOWN Sunnylands 2019 Working Group
Feb 6, 2021·Viruses·Marco BerrutiAntonio Di Biagio
Feb 10, 2021·Expert Opinion on Drug Safety·Julen CadiñanosJose R Arribas
Nov 3, 2020·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Giuliano RizzardiniDavid A Margolis
Feb 13, 2021·Viruses·Steven J SmithStephen H Hughes
Feb 18, 2021·The Annals of Pharmacotherapy·Spencer H Durham, Elias B Chahine
Feb 10, 2021·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Jacob A PluznikAnne C Spaulding
Nov 10, 2020·International Journal of Antimicrobial Agents·Charles FlexnerSusan Swindells
Feb 25, 2021·Current Opinion in HIV and AIDS·John Thornhill, Chloe Orkin
Mar 2, 2021·Frontiers in Immunology·Berend J van WelzenAndy I M Hoepelman
Oct 15, 2020·JAMA : the Journal of the American Medical Association·Michael S SaagPaul A Volberding
Dec 12, 2020·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Stephanie SpringIan Woolley

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.